FDA Delays Heart Drug Review, Sending Cytokinetics Inc Stock into Turmoil
Cytokinetics Inc’s stock price plummeted after the FDA delayed its review of the company’s lead heart drug, Aficamten, causing concerns about the company’s financial position and future prospects.
2 minutes to read